Findings Presented at ATS 2022 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 16, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced new data showing that its Percepta Nasal Swab test accurately assesses lung cancer risk among current and former smokers with lung nodules, regardless of their
Decipher Prostate test specifically cited for its extensive clinical evidence, including from multiple phase 3 randomized trials in high-risk prostate cancer SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 12, 2022-- Veracyte, Inc . (Nasdaq: VCYT) announced today that an updated clinical
Findings to Focus on Ability of Immunoscore IC Test to Predict Efficacy of Immune Checkpoint Inhibitors in Patients with NSCLC SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 12, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that six abstracts demonstrating the ability of its genomic and
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 4, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that new consensus data from a survey of leading breast cancer oncologists in Europe suggest the importance of gene expression profile (GEP) testing in guiding treatment decisions for women
Grew Total Revenue to $67.8 million , an Increase of 85% Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 3, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2022 .
Review article and commentary in AnnalsATS reinforce clinical utility of genomic test to improve confidence in IPF diagnosis, in conjunction with HRCT and clinical factors SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 2, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that an updated
Findings Provide New Insights into Genomic Underpinnings of Prostate and Bladder Cancers SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 28, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that three abstracts highlighting new data on the genomic underpinnings of prostate and bladder
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 26, 2022-- Veracyte, Inc . (Nasdaq: VCYT) announced today that new, expanded data demonstrating the performance of the company’s non-invasive Percepta Nasal Swab test in the evaluation of potentially cancerous lung nodules will be presented at
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 19, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the first quarter of 2022 after the close of market on Tuesday, May 3, 2022 . Company management will host a conference call and webcast to discuss
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 1, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley , chief executive officer, and Rebecca Chambers , chief financial officer, will participate in a presentation at Cowen’s 42 nd Annual Health Care Conference on March 8 th at
The information in our press releases and webcasts should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.
